Role of monocyte-to-lymphocyte ratio in predicting sorafenib response in patients with advanced hepatocellular carcinoma.

导出 LinkOut

翻译打印收藏纠错

第一作者： Zhenfeng,Zhu

第一单位： Department of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China, mengzhq@yeah.net.

作者： Zhenfeng,Zhu ^[1] ; Litao,Xu ^[2] ; Liping,Zhuang ^[1] ; Zhouyu,Ning ^[2] ; Chenyue,Zhang ^[1] ; Xia,Yan ^[2] ; Junhua,Lin ^[1] ; Yehua,Shen ^[2] ; Peng,Wang ^[1] ; Zhiqiang,Meng ^[2]

作者单位： Department of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China, mengzhq@yeah.net. ^[1] Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China, mengzhq@yeah.net. ^[2]

关键词 hepatocellular carcinoma monocyte-to-lymphocyte ratio prognosis sorafenib

DOI 10.2147/OTT.S173275

PMID 30349306

发布时间 2022-03-21

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览7

OncoTargets and therapy

2018年11卷

6731-6740页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Role of monocyte-to-lymphocyte ratio in predicting sorafenib response in patients with advanced hepatocellular carcinoma.

OncoTargets and therapy

相似文献

OncoTargets and therapy

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Role of monocyte-to-lymphocyte ratio in predicting sorafenib response in patients with advanced hepatocellular carcinoma.

OncoTargets and therapy

相似文献

OncoTargets and therapy

相关期刊

检索历史清除